Vaccine Manufacturers Need Plans To Cut Adventitious Agents By October
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is sending two rounds of letters to different sets of companies asking for the plans as part of the fall-out from the issues seen in rotavirus vaccines.
You may also be interested in...
Vaccine Safety Screening For Adventitious Agents Looms Large At Substrates Cmte.
FDA’s Vaccine and Related Biological Products Advisory Committee will examine the role of emerging technologies for detecting adventitious agents in assessing whether novel human tumor-derived cell-line substrates are suitable for vaccine production.
Vaccine Safety: Could More Outside Advisors For HHS Improve Public Perception?
An outside oversight group may be recommended to restore public confidence in vaccine safety, but several members of the National Vaccine Advisory Committee are not entirely sold that it is necessary.
Vaccine Safety: Could More Outside Advisors For HHS Improve Public Perception?
An outside oversight group may be recommended to restore public confidence in vaccine safety, but several members of the National Vaccine Advisory Committee are not entirely sold that it is necessary.